|Mr. Denis D. Corin||Chairman, CEO, Pres & CFO||240k||N/A||1973|
|Mr. William S. Rosenstadt||Gen. Counsel & Director||331.26k||N/A||1968|
|Mr. David Laskow-Pooley||VP of Product Devel.||N/A||N/A||1954|
|Mr. Robert Derham||VP of Orphan Products||N/A||N/A||N/A|
|Mr. Ari Jatwes||Bus. Devel. Analyst||N/A||N/A||N/A|
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a research collaboration with Chemveda Life Sciences India Private Limited for the synthesis of Uttroside B, which is isolated from the leaves of Solanum nigrum and its analogues for use in the clinical trials and treatment of hepatocellular carcinomas, and other targets and therapeutic areas. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.
Q BioMed Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.